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Abstract
Two human stromal cell lines were established previous-
ly from bone marrow-derived primary long-term cul-
tures by immortalization using the SV40 large T antigen
and cellular cloning. After irradiation, the fibroblast-like
cell lines L87/4 and L88/5 support hematopoietic differ-
entiation of allogeneic cord blood cells in vitro. The stro-
mal cells do not express CD34 and CD50, but some adhe-
sion molecules and integrins, such as CD44, CD54 and
CD58. Their expression profiles on RNA and protein lev-
els are suggestive of their osteogenic potency. The quali-
ty and quantity of osteocalcin and osteopontin protein
expression depended on the culture conditions. Expres-
sion of the osteogenic markers increased over time in
culture, especially in cells growing in clusters. The stro-
mal cells also expressed collagens I and V, but did not
show any expression of collagens II and III. The potential-
ly osteoblastic stromal cells were transplanted into NOD/
SCID recipient mice by intravenous injection and were
found in various mesenchymal organs up to 10 weeks
after transplantation. Osteocalcin-positive human stro-
mal cells could be detected in the bone marrow, thymus,
liver, brain and gut of the recipient animals. In summary,
there is evidence that human bone-marrow-derived stro-
mal cells have to be considered mesenchymal progeni-
tors, persistently expressing osteogenic markers in vitro
and in vivo.
Copyright © 2001 S. Karger AG, Basel
Introduction
In recent years, there has been increasing interest in the
plasticity of hematopoietic stem cells. In traditional un-
derstanding, hematopoietic differentiation requires the
support by growth factors provided by stromal cells. Stro-
mal cells are the major source of essential growth factors
and part of the stromal cell system which also consists of
mesenchymal stem cells and its progeny, connective tis-
sue cells and intercellular matrix proteins [1]. For many
years, bone marrow was considered to consist of three
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individual cellular components: hematopoietic, endothe-
lial and stromal cells. The mesenchymal stem cells within
the stromal compartment can differentiate into various
connective tissue lineages including osteogenic precursors
[2].
Stromal cells were defined as a fibroblast-like, adher-
ent cell population obtained by direct plating of bone
marrow cells. The diversity of marrow stroma compo-
nents depends on culture conditions and growth media.
Using a standard colony-forming unit-fibroblast (CFU-F)
assay, we generated a monoclonal stromal cell line from
canine bone marrow after immortalization of the adher-
ent cells with a human papilloma vIrus 16 E6E7 construct
[3, 4]. From this CD34-negative cell line designated D064
we generated CD34-positive, nonadherent hematopoietic
progenitors which also form other hematopoietic CFUs.
D064 cells can also function as ‘classical’ stromal cells
supporting the growth of allogeneic hematopoietic differ-
entiation in vitro. This supports the notion that a stromal-
like cell population can give rise to hematopoietic proge-
ny. A similar statement was made by Huang and Terstap-
pen in their controversial paper, proposing that a single
CD34-positive stem cell gives rise to CD34-negative stro-
mal cells as well as to committed hematopoietic precur-
sors [5, 6].
Since most of the CD34-negative fibroblast-like stro-
mal cells are predominantly quiescent and refractory to
external signalling, only a very small number of them can
differentiate into hematopoietic progenitors. The majori-
ty of CD34-negative stromal cells are not committed to
hematopoiesis, but can maintain and fulfil other func-
tions. Here we investigated, whether two well-established
human stromal cell lines function as mesenchymal stem
cells and display an osteogenic potency in vitro and in
vivo.
Material and Methods
FACS Analysis
The established human stromal cell lines L87/4 and L88/5 cells
were detached from culture flasks by collagenase/dispase (1 mg/ml,
Boehringer, Mannheim), washed with culture medium, counted and
adjusted to appropriate cell concentrations. 5–10 ! 105 cells were
used for FACS analysis. Cells were washed twice with IF buffer (2%
FCS, 0.01% NaN3 in PBS) and incubated with the antibodies to be
analyzed for 30 min at 4°C. Excessive antibody was removed by
washing the cells twice with cold IF buffer. Cells were then incubated
for 30 min at 4°C with a secondary PE or FITC-labeled antibody,
washed twice with cold IF buffer, resuspended in 1 ml IF buffer and
analyzed in a flow-cytometer (Becton Dickinson, CellQuest).
Osteocalcin and Osteopontin m-RNA Detection by RT-PCR
One microgram total cellular RNA isolated from monolayers of
L87/4 and L88/5 cells (Trizol, Gibco) was reverse transcribed by M-
MuLV reverse transcriptase (Promega) in a 10-Ìl RT assay (1 mM
dNTPs, 1 ! RT buffer, 100 ng oligo(dT)15, 10 U RNasin, 100 U
M-MuLV RT) for 1 h at 42 °C. PCR was performed in 25-Ìl reac-
tions with 5 Ìl of the RT product, 5 pmol of each primer (osteo-
calcin sense: 5)-ATGAGAGCCCTCACACTCCTCG-3); osteocal-
cin antisense: 5)-CCGGGCCGTAGAAGCGCCGATA-3); osteo-
pontin sense: 5)-CATTGACTCGAACGACTCTG-3), osteopontin
antisense: 5)-ACGGCTGTCCCAATCAGAAG-3)) and 0.75 U Taq
Polymerase (Sigma). cDNA was amplified in 40 cycles (58°C anneal-
ing temperature) followed by a final extension step (72°C, 7 min)
(thermocycler: Biozym). The amplified DNA was separated on a
1.2% agarose gel, stained with ethidium bromide and photographed.
Verification of the yielded osteocalcin PCR product was performed
by an internal restriction analysis.
Transplantation of L87/4 and L88/5 Cells into NOD/SCID Mice
NOD/SCID mice were irradiated with 2 Gy and transplanted 3 h
later with 2 ! 106 L87/4 or 2 ! 106 L88/5 cells by slow injection into
the tail vein. Control animals were irradiated without transplanta-
tion. 3, 6, and 10 weeks posttransplantation, 2 animals of each group
were sacrificed, organs were removed and imbedded in paraffin, sec-
tioned (1–2 Ìm) and analyzed immunohistochemically.
Immunohistochemical Investigation of Paraffin-Embedded
Tissues
Transplanted mice were sacrificed 3, 6, and 10 weeks posttrans-
plantation and tissues were immediately fixed overnight in buffered
4% formalin. Fixed tissues were embedded into paraffin and 1- to
2-Ìm sections were analyzed as follows: Deparaffinized slides were
pretreated in TRS6 (target retrieval) solution in a microwave oven
for 15 min at 800 W. Unspecific antibody-binding sites were blocked
by incubating the slides in ‘protein block serum free’ (DAKO) solu-
tion for 10 min. Subsequently, slides were incubated with primary
antibody (osteocalcin Biotrend, 1:300) for 60 min at room tempera-
ture and stained with an alkaline phosphatase coupled secondary
antibody (enVision Labelled Polymer-AP, DAKO). Binding was
visualized by incubating the slides in Fast Red® solution (Sigma) for
10 min.
Immunohistochemical Investigation of L87/4 and L88/5 Cells
Grown on Chamber Slides
L87/4 and L88/5 stromal cells were grown to 70% confluency in
Iscove’s/10% FCS medium in chamber slides. Slides were fixed with
4% paraformaldehyde for 20 min and digested with proteinase K
(1:1,000, Quiagen) for 15 min at room temperature. Unspecific anti-
body-binding sites were blocked by 50 min incubation in 20% FCS at
room temperature. Binding of primary antibodies (table 1) was per-
formed at 4°C overnight. Antibody binding was vizualized by the
ABC-peroxidase method (Vector, Burlingame, Calif., USA) as de-
scribed by the manufacturer. As positive controls for the primary
antibodies, the SaOS-2 osteosarcoma cell line as well as primary cul-
tures from human middle ear bone were analyzed. As negative con-
trols primary endothelial cells, primary fibroblasts and CHO cells
were used.
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Table 1. Antibodies against osteogenic
markers
Epitope Manufacturer Dilution
Osteocalcin Biotrend 1:400
Collagen I Quartett 1:50
Collagen II Quartett 1:50
Collagen III Quartett 1:75
Collagen V Quartett 1:100
Table 2. Immunophenotype of L87/4 and L88/5 cells
L87/4 L88/5
Miscellaneous antigens
CD10 ++ +
CD13 +++ ++
CD33, CD34, CD36, CD38, CD56 – –
CD68 + –
CD71 +++ ++
HLKA-DR, glycophorin A – –
Fc-receptors
CD16, CD23, CD32, CD64 – –
Adhesion molecules
CD11a, CD11b, CD11c, CD18 – –
CD29 +++ +++
CD44 +++ +++
CD49b ++ +
CD49d ++ –
CD49e +++ +++
CD49f +++ +++
CD54 +++ ++
CD58 +++ +++
CD50, CD61, CD62E, CD102, CD106 – –
Results
Surface Expression of the Mesenchymal Stem Cell
Markers in Human Stromal Cell Lines L87/4 and
L88/5
To characterize the mesenchymal phenotype of L87/4
and L88/5 stromal cells, we analyzed the surface expres-
sion of known mesenchymal markers by FACS analysis.
For the generation of these data both cell lines were grown
in monolayer cultures without stimuli. As shown in
table 2, L87/4 and L88/5 cells did not express CD50, a
marker which has been described for stromal components
giving rise to hematopoietic progeny, while CD50 is not
found on mesenchymal progenitors. Quiescent L87/4 and
L88/5 cells did not express typical differentiation markers
like Mac1 (CD11b), CD34, or HLA-DR. Both cell lines
were positive for the adhesion molecules ICAM-1
(CD54), LFA-3 (CD58) and HCAM (CD44), molecules
known to be important for the interaction of mesenchy-
mal stem cells with hematopoietic progenitors (table 2).
According to their colony forming potential in soft agar
[8], L87/4 and L88/5 cells expressed the surface markers
CD10, CD13, and the CD29/CD49 family of integrins
(table 2) which are characteristically found on CFU-F pre-
cursor cells.
Additionally, both cell lines produced a variety of
growth factors (Il-1, IL-6, IL-7, IL-8, IL-11, LIF, M-CSF,
SCF, G-CSF, GM-CSF) known to be essential for a func-
tion as feeder layers in long-term cultures of hematopoiet-
ic cells [7].
Osteogenic Potential of L87/4 and L88/5 Cell Lines
In order to analyze the mesenchymal differentiation
potential of L87/4 and L88/5 stromal cells, we first per-
formed RT-PCR reactions specific for the osteogenic
marker genes osteocalcin and osteopontin. As shown in
figure 1, both cell lines expressed osteocalcin as well as
osteopontin mRNA.
Osteocalcin protein expression was demonstrated by
immunohistochemistry. As positive control we used the
osteocalcin-expressing human osteosarcoma cell line
SaOS-2 and primary cultures from middle ear bones.
Depending on culture conditions, varying percentages of
L87/4 and L88/5 cells stained positive for osteocalcin
(fig. 2).
Cells belonging to the osteogenic differentiation path-
way are expected to express collagens I and V while being
negative for collagens II and III. To characterize the
osteogenic potential of L87/4 and L88/5 stromal cells, we
analyzed the expression of collagen I, II, III, and V immu-
nohistochemically. To generate these data, the cell lines
were grown in monolayers on chamber slides without any
stimuli. The osteosarcoma cell line SaOS-2 as well as pri-
mary cultures of middle ear bones served as positive con-
trols. As expected, SaOS-2 cells (fig. 3) and primary
osteogenic cells stained positive for collagens I and V,
while they did not show any signal for collagens II and III.
Analyzed with these highly specific antibodies, L87/4 and
L88/5 cells strongly express the typical osteogenic mark-
ers collagen I and V, while we did not get any signal on the
cells with antibodies against collagens II and III (fig. 3).
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Fig. 1. Osteocalcin and osteopontin expresssion in L87/4 and L88/5
cells. 1 Ìg of total RNA of L87/4 and L88/5 cells was analyzed by
RT-PCR using primers against osteocalcin and osteopontin. PCR
products were separated on 1.2% agarose gels and visualized by
ethidium bromide staining.
Organ Distribution of L87/4 and L88/5 Cells in
NOD/SCID Mice
Accumulating experimental evidence shows that mes-
enchymal stem cells are able to differentiate into a variety
of organ-specific cell types after transplantation into
NOD/SCID mice. To analyze the capacity of organ-spe-
cific homing and differentiation of L87/4 and L88/5 cells,
we transplanted both cell lines into irradiated NOD/SCID
mice. Organs of the transplanted mice were collected 3, 6
and 10 weeks posttransplantation, embedded into paraf-
fin and stained immunohistochemically. To show the dif-
ferentiation status of the human transplants in murine
tissue background, we used a human-specific antibody
against osteocalcin. Since osteocalcin-positive cells
seemed to persist at an extremely low number, we also
stained the slides with an antibody against SV40 large T
antigen as an additional specific marker for the trans-
planted human cells. We could show that up to 10 weeks
posttransplantation both cell lines persisted in the bone
marrow, the brain, the liver, the thymus and the gut of the
transplanted animals (fig. 4).
Discussion
The two well-established human stromal cell lines L87/
4 and L88/5 are commonly used to support human hema-
topoietic cells in vitro [7, 8]. Some years ago, it was alrea-
dy reported that STRO-1+ adult human bone marrow
contains osteogenic precursors [9]. To test the hypothesis
of a common population of stromal, mesenchymal stem
cells and even hematopoiesis, we investigated the osteo-
genic potential of the two stromal cell lines mentioned
above. The phenotypic analysis revealed an expression
pattern common of established stromal cell lines, but,
additionally, the expression of osteogenic markers such as
osteocalcin and osteopontin in a certain number of the
stromal cells [10, 11]. Expression of the osteogenic mark-
ers increased over time in culture, especially in cells grow-
ing in clusters. Both cell lines, L87/4 and L88/5, expressed
type I and type V collagen, indicative of bone precursors
[12, 13], while they did not show any expression of types
II and III collagens. This is suggestive for traditional stro-
mal cells having the potential to function as osteogenic
progenitors. After transplantation into NOD/SCID mice,
human stromal cells also persisted in various mesenchy-
mal organs. Human osteocalcin-positive L87/4 and L88/5
cells were not only found in capillary vessels of the lung,
liver and bone marrow, but were also well suited in the
thymus and the central nervous system. Therefore, hu-
man bone marrow-derived stromal cells have to be con-
sidered mesenchymal precursors which can persist in var-
ious organ sites of the recipient animals. The importance
of these data becomes clear in view of the current discus-
sion about the plasticity of stem cells [14], since these plu-
ripotent stem cells can be isolated from various tissues
In vivo Differentation of Human Stromal
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Fig. 2. Immunohistochemical staining of osteocalcin
in SaOS-2 and L88/5 cells SaOS-2 and L8875 cells
were grown on chamber slides, fixed, air-dried and
incubated with a polyclonal antibody against osteo-
calcin. Antibody binding was visualized by the ABC-
peroxidase method. A high percentage (180%) of
SaOS-2 cells were positive for osteocalcin, while L88/
5 cells showed variable protein expression, depending
on the cell cycle status.
Fig. 3. Collagen expression of SaOS-2, L87/4 and L88/5 cells SaOS-
2, L87/4 and L88/5 cells were grown in monolayer cultures on cham-
ber slides, fixed in paraformaldehyde and air-dried. Cells were incu-
bated with antibodies against collagens I, II, III and V and binding
was visualized by the ABC-peroxidase method. All three cell lines
showed a collagen expression pattern typical for cells of the osteogen-
ic differentiation pathway, positive for collagens I and V, negative for
collagens II and III.
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Fig. 4. Immunohistochemical detection of transplanted L87/4 cells in different tissues of NOD/SCID mice. NOD/SCID mice were
transplanted with L87/4 cells and sacrificed 10 weeks posttransplantation. Murine tissues were imbedded into paraffin, sectioned
and analyzed immunohistochemically. As indicated above (arrow), single osteocalcin-positive L87/4 cells were present in the bone
marrow, thymus, liver and brain of the transplanted animals
and even peripheral blood where they exist as circulating
stem cells [15–17].
As of yet, hematopoietic and repopulating stem cells
have been identified by surface expression of CD34 anti-
gen. There were some publications in recent years demon-
strating that CD34-negative cells can also reconstitute the
complete lympho-hematopoietic system of mice and
sheep [18–22]. Although evidence is controversial , stro-
mal cells as well as mesenchymal stem cells are considered
to be CD34-negative [23]. Our own experiments showed
that CD34-positive hematopoietic progenitors can be gen-
erated from CD34-negative, stroma-like precursors [24].
In culture, approximately 0.1% of the L87/4 and L88/5
stromal cells express CD34 even spontaneously [unpubl.].
The phenotype of a mesenchymal cell line seems to
depend on cell culture conditions. Grown in monolayer
cultures, our two cell lines do not express CD50 and
CD34 while they are positive for CD44, CD49e and
CD49f. This expression pattern is consistent with the phe-
notype of described mesenchymal cells [1]. According to
other reports, mesenchymal stem cells express CD106
(VCAM), but are negative for CD49d. VCAM was not
found in either cell line, L87/4 and L88/5, but the former
was positive for CD49d. Depending on cell culture condi-
In vivo Differentation of Human Stromal
Cells
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tions, different phenotypes of mesenchymal precursor
cells could be observed, although the cell lines are mor-
phologically and functionally closely related.
Recent reports suggested the clinical use of mesenchy-
mal stem cells isolated from bone marrow [25]. Our
results provide further evidence that even marrow stro-
mal cell lines can be used to generate distinct mesenchy-
mal organ tissue such as bone tissue, depending on cell
culture conditions. Most of the growth factors which play
a pivotal role in directing differentiation of quiescent
stem cells towards specialization are produced in an auto-
crine and paracrine fashion by stromal cells [7, 26]. There-
fore, stromal cells might be the essential link between
mesenchymal stem cells and quiescent hematopoietic
progenitors which we could identify as CD34-negative,
fibroblast-like cells [27, 28]. It is even probable that there
is a common progenitor cell to all three cell types, the
function of which is determined by the ultimate demand
within an organism.
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